Scienture Holdings, Inc. (NASDAQ:SCNX) shares jumped 21.25% to $0.4046 in overnight trading at the time of writing, adding to a 0.48% Thursday surge.
Naloxone Spray Nears Market Launch
The stock move came after the New York-based comprehensive health services and pharmaceutical company announced before Thursday’s market open that it had completed manufacturing of commercial launch inventory for REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg. The company said shipments to U.S. pharmaceutical wholesalers are expected to begin later this month.
REZENOPY is the highest-dose Food and Drug Administration-approved naloxone nasal spray available in the U.S. It delivers a 10 mg dose through a single-use device to reverse known or suspected opioid overdoses, including those involving powerful synthetic opioids. The FDA approved the treatment in April 2024.
Retail availability is expected in August, with the company working alongside wholesale distribution partners nationwide.
Prior Product Launch
Shankar Hariharan, Executive Chairman and co-CEO of Scienture, said the company is “well positioned to make REZENOPY broadly available to pharmacies, healthcare providers, first responders, and community organizations in August.”
The REZENOPY milestone follows Scienture’s October 2025 launch of Arbli, the first FDA-approved ready-to-use liquid formulation of the blood pressure medication losartan.
Trading Metrics, Technical Analysis
Scienture Holdings has a market capitalization of $13.53 million, with a 52-week high of $2.60 and a 52-week low of $0.23.
Volume for the day rose to 7.82 million shares, approximately 19.6 times the stock’s average daily volume of 398,400 shares, indicating significantly elevated trading activity.
The Relative Strength Index (RSI) of SCNX stands at 34.79, while short interest is at 3.10%.
Over the past 12 months, the stock has dropped 79.19%.
SCNX is currently trading near its 52-week low.
Price Action: The stock had closed on Thursday at $0.33, according to Benzinga Pro data.
Benzinga’s Edge Stock Rankings indicate that SCNX has a negative price trend across all time frames.
Photo courtesy: Zakharchuk / Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Login to comment